Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib

Overview of attention for article published in Biologics: Targets & Therapy, February 2016

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 17 publications that cite this research output.

17

The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.

Assessment of knowledge, attitudes, and practices of CML patients and their families toward TKI therapy in China

Article in Medicine (December 2023)

Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China

Article in PLOS ONE (October 2021)

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy

Article in PharmacoEconomics - Open (July 2021)